XOMA receives final $2.0 million from Kaketsuken under antibody technology collaboration

NewsGuard 100/100 Score

XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced receipt of the final $2.0 million payment from Kaketsuken under the $8.0 million collaboration announced in November 2009. The agreement involves multiple proprietary XOMA antibody research and development technologies, including a new XOMA phage display library, and a suite of integrated information and data management systems. XOMA will be entitled to milestone payments and royalties on sales from products arising from this collaboration. The $8.0 million fee paid by Kaketsuken was recorded by XOMA as revenue in the 2009 fourth quarter.

"XOMA's antibody technology collaborations are designed to enable our partners to advance their drug discovery and optimization programs and provide an important source of revenue to the company. We look forward to additional revenue-generating antibody technology collaborations such as this successful arrangement with Kaketsuken," said XOMA Chairman and Chief Executive Officer Steven B. Engle.

Source XOMA Ltd.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Phase 1 trial for EBC-129 progresses into dose expansion